https://www.healio.com/news/neurology/20251121/fenebrutinib-reduces-msrelated-inflammatory-disease-activity-up-to-2-years
Treatment with fenebrutinib in a 2-year open-label extension study led to significantly reduced disease-related inflammatory activity in those with relapsing...
inflammatory diseasefenebrutinibreducesmsrelated